FHTX insider transaction filings
Foghorn Therapeutics Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-25. Screen FHTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Biller Scott — Director | 1 | — | — | 1 |
| Cole Douglas G. — Director | 1 | — | — | 1 |
| Duty Stuart — Director | 1 | — | — | 1 |
| GILL SIMBA — Director | 1 | — | — | 1 |
| Gallagher Neil — Director | 1 | — | — | 1 |
| Lynch Thomas J. Jr. — Director | 1 | — | — | 1 |
| Mendelsohn Michael — Director | 1 | — | — | 1 |
| PARSHALL B LYNNE — Director | 1 | — | — | 1 |
| SMITH IAN F — Director | 1 | — | — | 1 |
Recent Form 4 filings — Foghorn Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-25 | 4 | Gallagher Neil — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | Duty Stuart — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | Mendelsohn Michael — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | Biller Scott — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | Cole Douglas G. — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | Lynch Thomas J. Jr. — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | SMITH IAN F — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | GILL SIMBA — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-06-25 | 4 | PARSHALL B LYNNE — Director | Grant/award (A): 28,000 (derivative) @ $4.08 | EDGAR |
| 2026-04-13 | 4 | GOTTSCHALK ADRIAN — Chief Executive Officer, Director | Gift (G): 47,497 @ $0 · Gift (G): 47,497 @ $0 · Gift (G): 59,208 @ $0 · Gift (G): 59,208 @ $0 | EDGAR |
| 2026-02-24 | 4 | Maynard Ryan D — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $5.75 | EDGAR |
| 2026-02-06 | 4 | GOTTSCHALK ADRIAN — Chief Executive Officer, Director | Grant/award (A): 1,075,000 (derivative) @ $5.23 | EDGAR |
| 2026-02-02 | 4 | Rivkin Anna — Chief Business Officer | Grant/award (A): 165,000 (derivative) @ $5.71 | EDGAR |
| 2026-02-02 | 4 | Costa Carlos — Chief People Officer | Grant/award (A): 230,000 (derivative) @ $5.71 | EDGAR |
| 2026-02-02 | 4 | LaCascia Michael — Chief Legal Officer | Grant/award (A): 295,000 (derivative) @ $5.71 | EDGAR |
| 2026-02-02 | 4 | Bellon Steven F. — Chief Scientific Officer | Grant/award (A): 300,000 (derivative) @ $5.71 | EDGAR |
| 2026-02-02 | 4 | Cardama Alfonso Quintas — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $5.71 | EDGAR |
| 2026-01-15 | 4 | Flagship Pioneering, LLC — Director, 10% owner Flagship Pioneering Fund VII General Partner LLC — Director, 10% owner Flagship Pioneering Fund VII, L.P. — Director, 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC — Director, 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. — Director, 10% owner Flagship Ventures Fund V General Partner LLC — Director, 10% owner Flagship Ventures Fund V, L.P. — Director, 10% owner Flagship Ventures Opportunities Fund I General Partner LLC — Director, 10% owner Flagship Ventures Opportunities Fund I, L.P. — Director, 10% owner AFEYAN NOUBAR — Director, 10% owner | Grant/award (A): 2,235,468 (derivative) @ $6.71 · Grant/award (A): 1,117,734 (derivative) · Grant/award (A): 1,117,734 (derivative) | EDGAR |
| 2025-11-17 | 4 | Humer Kristian — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2025-06-17 | 4 | Mendelsohn Michael — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | Biller Scott — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | Cole Douglas G. — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | Lynch Thomas J. Jr. — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | SMITH IAN F — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | GILL SIMBA — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-06-17 | 4 | PARSHALL B LYNNE — Director | Grant/award (A): 25,000 (derivative) @ $4.79 | EDGAR |
| 2025-05-02 | 4 | Gallagher Neil — Director | Grant/award (A): 50,000 (derivative) @ $4.16 | EDGAR |
| 2025-05-02 | 4 | Duty Stuart — Director | Grant/award (A): 50,000 (derivative) @ $4.16 | EDGAR |
| 2025-04-28 | 4 | GOTTSCHALK ADRIAN — Chief Executive Officer, Director | Gift (G): 300,000 @ $0 · Gift (G): 300,000 @ $0 | EDGAR |
| 2025-04-10 | 4 | GOTTSCHALK ADRIAN — Chief Executive Officer, Director | Gift (G): 197,906 @ $0 · Gift (G): 197,906 @ $0 | EDGAR |
| 2025-01-24 | 4 | Humer Kristian — Chief Financial Officer | Grant/award (A): 120,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | Costa Carlos — Chief People Officer | Grant/award (A): 115,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | Rivkin Anna — Chief Business Officer | Grant/award (A): 50,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | GOTTSCHALK ADRIAN — Chief Executive Officer, Director | Grant/award (A): 400,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | Bellon Steven F. — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | LaCascia Michael — Chief Legal Officer | Grant/award (A): 126,000 (derivative) @ $4.37 | EDGAR |
| 2025-01-24 | 4 | Cardama Alfonso Quintas — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $4.37 | EDGAR |
| 2024-12-30 | 4 | Koppel Adam — Director | Holdings only — no transactions reported | EDGAR |
| 2024-09-24 | 4 | Costa Carlos — Chief People Officer | Option exercise (M): 35,756 @ $3.72 · Sale (S): 35,756 @ $10.04 · Option exercise (M): 857 @ $3.72 · Sale (S): 857 @ $10.17 · Option exercise (M): 35,756 (derivative) @ $0 · Option exercise (M): 857 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Costa Carlos — Chief People Officer | Option exercise (M): 11,574 @ $3.72 · Sale (S): 11,574 @ $10.05 · Option exercise (M): 11,574 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Costa Carlos — Chief People Officer | Option exercise (M): 400 @ $3.72 · Sale (S): 400 @ $10 · Option exercise (M): 10,272 @ $3.72 · Sale (S): 10,272 @ $10.04 · Option exercise (M): 400 (derivative) @ $0 · Option exercise (M): 10,272 (derivative) @ $0 | EDGAR |
| 2024-09-11 | 4 | Bellon Steven F. — Chief Scientific Officer | Sale (S): 20,000 @ $9.50 | EDGAR |
| 2024-09-04 | 4 | Rivkin Anna — Chief Business Officer | Grant/award (A): 190,000 (derivative) @ $7.85 | EDGAR |
| 2024-06-28 | 4 | Biller Scott — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | Koppel Adam — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | Cole Douglas G. — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | Lynch Thomas J. Jr. — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | SMITH IAN F — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | GILL SIMBA — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
| 2024-06-28 | 4 | PARSHALL B LYNNE — Director | Grant/award (A): 16,000 (derivative) @ $5.52 | EDGAR |
Recent 8-K events — Foghorn Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FHTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →